



Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer


SUPPLEMENTARY FIGURES




Supplementary Figure 1: Interaction of Myc-EGFR and V5-PHD2 in HEK-293 cells. The specificity of V5-tag and Myc-tag antibodies used for the detection of EGFR-PHD2 interaction was verified by Western Blot analysis of immunoprecipitates (IP) and whole-cell extracts (WCE) from non-transfected HEK-293 cells, and HEK-293 cells overexpressing either V5-tagged PHD2 and/or Myc-EGFR. **A.** Blots from anti-V5 IPs were probed with Myc-tag antibody. WCEs were probed with V5-tag, Myc-tag and α -tubulin antibodies. **B.** Blots from 'reverse' anti-Myc IPs were probed with V5-tag antibody. WCEs were probed with V5-tag, Myc-tag and α -tubulin antibodies. **C.** WB analysis of immunoprecipitates (IP) and whole-cell extracts (WCE) from HEK-293 cells, overexpressing V5-tagged PHD2 variants and Myc-EGFR. Blots from anti-Myc IPs were probed with V5-tag antibody. WCEs were probed with V5-tag, Myc-tag and α -tubulin antibodies. **D.** Quantification of the interaction between Myc-EGFR and V5-PHD2 variants from the 'reverse' immunoprecipitation. The levels of Myc-EGFR-bound wt V5-PHD2 from the lysates expressing wt PHD2 and Myc-EGFR (respective control) were set to 1. * significant difference between the precipitated V5-PHD2 levels from the lysates of HEK-293, expressing mut, $\Delta 1-139$ or $\Delta 208-426$ variants vs. control.




Supplementary Figure 2: MDA-MB-231 PHD2 knockdown clones #3 and #4 exhibit normoxic accumulation of HIF-1 α and HIF-2 α levels. WB analysis in the WCEs of MDA-MB-231 shC, #3, and #4 cells cultured under normoxia (16% O₂) or hypoxia (5% O₂) for 6 h. WCEs were probed with HIF-1 α , HIF-2 α , and α -tubulin antibodies.



Supplementary Figure 3: PHD2 knockdown leads to a less sustained activation of EGFR in PHD2 knockdown clone #4. MDA-MB-231 shC control and PHD2 knockdown #4 cells were treated with either vehicle or EGF (100 ng/ml) for 0, 1, 5, 10, 30, 60 min. The phosphorylation of EGFR was measured with a phosphospecific antibody. **A.** Representative immunoblot of EGF receptor phosphorylation in MDA-MB-231 shC control and PHD2 knockdown cells. **B.** Quantification of EGFR activity. The ratio of phosphorylated EGFR to total EGFR levels in untreated shC control cells was set equal to 1. * significant difference PHD2 knockdown cells vs. same time point shC control cells.



Supplementary Figure 4: PHD2 knockdown fosters EGFR degradation in PHD2 knockdown clone #4. **A.** Representative immunoblots of EGFR levels in the lysates of MDA-MB-231 shC control and PHD2 knockdown #4 cells, pre-treated with translation inhibitor cycloheximide (10 mM) for 12 h and treated with EGF (100 ng/ml) for 0, 1, 2, 3, 4 h. **B.** Quantification of EGFR levels in MDA-MB-231 cells treated with cycloheximide. The ratio of total EGFR to α -tubulin in non-treated shC control cells was set equal to 1. *significant difference PHD2 knockdown cells vs. shC control cells at the same time point. The statistical comparison between groups was performed by using Student’s two-tailed *t*-test. * $p \leq 0.05$. The time needed to reach 50% of the EGFR starting level is referred to as half-life of the receptor, and is marked with ◆ in PHD2 knockdown #4 cells.



Supplementary Figure 5: PHD2 knockdown does not influence the expression levels of SRC, CBL and CIN85.
Representative immunoblots of the S, CBL, CIN85 in the lysates of MDA-MB-231 shC control and PHD2 knockdown #3 and #4 cells.